RxDoctor Payments Data

Eng Kock Tan, MD

Psychiatry · Astoria, NYNPI 1932236064

Payments from drug & device makers

$7,421in general payments, 2019–2025

Across 285 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Alkermes, Inc.$1K
  • Johnson & Johnson$867
  • Teva Pharmaceuticals USA, Inc.$807
  • AbbVie$541
  • plus $1K from 6 others

What the payments were for

  • Food & beverage$7,421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,421 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$14,945
Medicare patients
13
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate99$300,672
Abilify MaintenaAripiprazole101$257,562
IngrezzaValbenazine Tosylate21$131,658
LybalviOlanzapine/Samidorphan Malate26$38,469
Lurasidone Hcl26$13,526
RisperdalRisperidone12$10,554
Olanzapine OdtOlanzapine18$5,867
Divalproex Sodium ErDivalproex Sodium67$5,451
Haloperidol Decanoate65$3,332
Clozapine56$1,829
Olanzapine88$1,276
Quetiapine Fumarate41$1,118
Divalproex Sodium12$611
Fluvoxamine Maleate13$543
Haloperidol33$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal$867$311,226111 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,163$257,562101 claims
Neurocrine Biosciences, Inc.Ingrezza$1,821$131,65821 claims
Alkermes, Inc.Lybalvi$1,158$38,46926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →